Gentiel develops therapeutic vaccines for the prevention of cervical cancer in HPV infected women.
Genticel is a French clinical stage biotechnology company founded by Benedikt Timmerman in 2001 and focused on the development of innovative immunotherapies designed to treat virus infections and virus-induced diseases. Genticel aims to become a leader in immunotherapy in multiple indications, starting with HPV and HPV induced diseases such as cervical cancer.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 24, 2013 | Series D | €18.20M | 1 | — | — | Detail |
Apr 5, 2010 | Series C | $17.70M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
InnoBio Fund | — | Series D |